BACKGROUND: The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002. METHODS: By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 patients were identified who had resected stage I, II, or IIIA NSCLC between 1992 and 2002 and survived >or=120 days beyond diagnosis. The rate of perioperative chemotherapy use was measured by calendar year, and the association between clinical/demographic characteristics and the receipt of chemotherapy was examined by using logistic regression. RESULTS: In total, 957 patients with stage I, II, or IIIA NSCLC (8.1% of the study population) received perioperative chemotherapy. The proportion of patients receiving chemotherapy for stage I NSCLC changed little during the study period. Of 3230 patients with stage II and IIIA NSCLC, 609 patients (18.9%) received chemotherapy, 423 patients (13%) received chemotherapy combined with radiation. 452 patients (15.6%) received adjuvant chemotherapy, and 66 patients (2.3%) received neoadjuvant chemotherapy. The use of chemotherapy increased significantly among patients who were diagnosed after 1994 relative to patients who were diagnosed in 1992 after controlling for sociodemographic and treatment characteristics (P< .001). There was significantly increased use of new-generation chemotherapy agents, such as carboplatin and taxanes (P< .001). The proportion of patients receiving combined-modality therapy also increased significant (P< .001). Younger age, being married, having advanced-stage tumor or adenocarcinoma, having a later diagnosis year, receiving radiation, and seeing an oncologist were predictors for the receipt of chemotherapy (P< .001). CONCLUSIONS: A substantial proportion of Medicare beneficiaries with NSCLC received perioperative chemotherapy. Specifically designed prospective trials that focus on older patients are needed.
BACKGROUND: The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002. METHODS: By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 patients were identified who had resected stage I, II, or IIIA NSCLC between 1992 and 2002 and survived >or=120 days beyond diagnosis. The rate of perioperative chemotherapy use was measured by calendar year, and the association between clinical/demographic characteristics and the receipt of chemotherapy was examined by using logistic regression. RESULTS: In total, 957 patients with stage I, II, or IIIA NSCLC (8.1% of the study population) received perioperative chemotherapy. The proportion of patients receiving chemotherapy for stage I NSCLC changed little during the study period. Of 3230 patients with stage II and IIIA NSCLC, 609 patients (18.9%) received chemotherapy, 423 patients (13%) received chemotherapy combined with radiation. 452 patients (15.6%) received adjuvant chemotherapy, and 66 patients (2.3%) received neoadjuvant chemotherapy. The use of chemotherapy increased significantly among patients who were diagnosed after 1994 relative to patients who were diagnosed in 1992 after controlling for sociodemographic and treatment characteristics (P< .001). There was significantly increased use of new-generation chemotherapy agents, such as carboplatin and taxanes (P< .001). The proportion of patients receiving combined-modality therapy also increased significant (P< .001). Younger age, being married, having advanced-stage tumor or adenocarcinoma, having a later diagnosis year, receiving radiation, and seeing an oncologist were predictors for the receipt of chemotherapy (P< .001). CONCLUSIONS: A substantial proportion of Medicare beneficiaries with NSCLC received perioperative chemotherapy. Specifically designed prospective trials that focus on older patients are needed.
Authors: S M Keller; S Adak; H Wagner; A Herskovic; R Komaki; B J Brooks; M C Perry; R B Livingston; D H Johnson Journal: N Engl J Med Date: 2000-10-26 Impact factor: 91.245
Authors: Laura-Mae Baldwin; Walter Adamache; Carrie N Klabunde; Kevin Kenward; Celia Dahlman; Joan L Warren Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Craig C Earle; Peter J Neumann; Richard D Gelber; Milton C Weinstein; Jane C Weeks Journal: J Clin Oncol Date: 2002-04-01 Impact factor: 44.544
Authors: R Rosell; E Felip; J Maestre; J M Sanchez; J J Sanchez; J L Manzano; J Astudillo; M Taron; M Monzo Journal: Lung Cancer Date: 2001-12 Impact factor: 5.705
Authors: F A Greco; H A Burris; J R Gray; E L Raefsky; C Dobbs; S Smith; D Rinaldi; L H Morrissey; J B Erland; S Litchy; J D Hainsworth Journal: Cancer Date: 2001-10-15 Impact factor: 6.860
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: R Rosell; U Gatzemeier; D C Betticher; U Keppler; H N Macha; R Pirker; P Berthet; J L Breau; P Lianes; M Nicholson; A Ardizzoni; A Chemaissani; J Bogaerts; G Gallant Journal: Ann Oncol Date: 2002-10 Impact factor: 32.976
Authors: Carmela Pepe; Baktiar Hasan; Timothy L Winton; Lesley Seymour; Barbara Graham; Robert B Livingston; David H Johnson; James R Rigas; Keyue Ding; Frances A Shepherd Journal: J Clin Oncol Date: 2007-04-20 Impact factor: 44.544
Authors: Jennifer L Lund; Til Stürmer; Linda C Harlan; Hanna K Sanoff; Robert S Sandler; Maurice Alan Brookhart; Joan L Warren Journal: Med Care Date: 2013-05 Impact factor: 2.983
Authors: Lauren E Cipriano; Dorothy Romanus; Craig C Earle; Bridget A Neville; Elkan F Halpern; G Scott Gazelle; Pamela M McMahon Journal: Value Health Date: 2011-01 Impact factor: 5.725
Authors: Rhami Khorfan; David T Cooke; Robert A Meguid; Leah Backhus; Thomas K Varghese; Farhood Farjah; Karl Y Bilimoria; David D Odell Journal: J Thorac Cardiovasc Surg Date: 2020-07-29 Impact factor: 6.439